Processa CAO converts 193 RSUs to common shares

Processa Pharmaceuticals, Inc. reported an equity award transaction by Chief Administrative Officer Wendy Guy.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. reported an equity award transaction by Chief Administrative Officer Wendy Guy. On January 1, 2026, 193 restricted stock units converted into 193 shares of common stock at a price of $0 per share, described as a distribution of vested restricted shares. Following the transaction, Guy beneficially owned 1,256 shares of common stock directly and 333 shares indirectly through CorLyst, LLC.

Insider Trade Summary

193 shares exercised/converted

Exercise 3 txns

Insider Guy Wendy

Role Chief Administrative Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	193	$0.00	$0.00
Exercise	Common Stock	193	$0.00	$0.00
holding	Common Stock	--	--	--

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 1,256 shares (Direct); Common Stock — 333 shares (Indirect, By CorLyst, LLC)

Footnotes (1)

F1. Distribution of vested restricted shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did PCSA report for Chief Administrative Officer Wendy Guy?

Processa Pharmaceuticals reported that Chief Administrative Officer Wendy Guy had 193 restricted stock units convert into 193 shares of common stock at $0 per share on January 1, 2026. This reflects a distribution of vested restricted shares under her equity compensation.

How many Processa Pharmaceuticals (PCSA) shares does Wendy Guy own after this Form 4?

After the reported transaction, Wendy Guy beneficially owned 1,256 shares of Processa Pharmaceuticals common stock directly. She also had indirect beneficial ownership of 333 additional common shares held through CorLyst, LLC, as disclosed in the Form 4 holding information.

What does the Form 4 code M mean in the PCSA filing for Wendy Guy?

In this Form 4, transaction code M indicates the conversion of derivative securities into common stock. Specifically, 193 restricted stock units converted into 193 shares of Processa Pharmaceuticals common stock at $0 per share on January 1, 2026, reflecting vested equity.

How were the restricted stock units treated in the PCSA Form 4 for Wendy Guy?

The filing shows 193 restricted stock units converted into 193 shares of common stock at $0 per share. An explanatory note states this was a distribution of vested restricted shares, indicating the units had vested and were delivered as common stock.

What indirect Processa (PCSA) holdings are reported for Wendy Guy on this Form 4?

The Form 4 discloses that, in addition to her direct holdings, Wendy Guy has indirect beneficial ownership of 333 shares of Processa Pharmaceuticals common stock. These shares are held "By CorLyst, LLC," as indicated in the nature of indirect beneficial ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/04/2026 - 05:05 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guy Wendy

(Last)

(First)

(Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH

32960

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Administrative Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/01/2026		M		193	A	$0⁽¹⁾	1,256	D
Common Stock								333	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	01/01/2026		M			193	⁽¹⁾	⁽¹⁾	Common Stock	193	$0	0	D

Explanation of Responses:

1. Distribution of vested restricted shares.

	/s/ Wendy Guy by John J. Wolfel, as Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR